TRPM3 Inhibitor for Migraine Treatment via CGRP Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for migraine, including CGRP inhibition and triptans, often lead to medication overuse headaches and are ineffective for a significant portion of patients, highlighting the need for alternative therapeutic approaches that target different pathways involved in migraine pathogenesis.
Innovation Solution
Development of an inhibitor for human TRPM3, which can be used alone or in combination with other therapies to treat or prevent migraines, trigeminal neuralgia, and other pain disorders by reducing the production of CGRP and PACAP, and identifying suitable patients through genetic sequencing and functional assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CGRP inhibition therapy is used for migraine treatment, then migraine prevention is improved, but effectiveness is reduced in a significant portion of patients who do not respond to CGRP inhibition
Solution Approach 1:
The patent changes the therapeutic target from CGRP to TRPM3, a different molecular parameter in the migraine pathogenesis pathway. This allows treatment of patients who do not respond to CGRP inhibition by targeting an alternative mechanism (TRPM3 channel activity) that is also involved in migraine pathology, thereby improving adaptability across different patient populations while maintaining reliability of migraine prevention
Solution Approach 2:
The patent introduces TRPM3 as an intermediary target between existing migraine treatments and the underlying pathology. By inhibiting TRPM3, the therapy indirectly affects downstream pathways including CGRP release and other neurochemical pathways, providing a bridge that can benefit patients who fail direct CGRP inhibition while still addressing the core migraine mechanism
2Ease of operation
If triptan therapy is used for migraine treatment, then acute relief is improved, but medication overuse headache develops with regular use
Solution Approach 1:
The patent extracts the acute relief function from triptans and separates it from the harmful overuse effects by targeting TRPM3 instead. TRPM3 inhibition provides a different mechanism for achieving migraine relief that does not rely on the same vasoconstrictive pathway as triptans, thereby maintaining effectiveness while eliminating the medication overuse headache problem
Solution Approach 2:
The patent transitions from using short-acting triptans that require frequent administration (leading to overuse) to a TRPM3 inhibitor that can provide sustained protection with less frequent dosing. This reduces the need for regular medication use while maintaining acute relief capability, thereby preventing medication overuse headache
3Reliability
If new migraine treatment pathways are developed, then effectiveness for non-responders is improved, but treatment complexity increases
Solution Approach 1:
The patent makes TRPM3 inhibition a universal treatment that can serve both CGRP-responsive and CGRP-non-responsive patients through a single mechanism. By targeting TRPM3, which is upstream of multiple downstream pathways including CGRP release, the treatment achieves multi-functionality that simplifies the overall treatment strategy while improving effectiveness across different patient subgroups
Solution Approach 2:
The patent merges the treatment of previously distinct patient groups (CGRP responders and non-responders) into a single therapeutic approach using TRPM3 inhibition. This consolidation reduces treatment complexity by eliminating the need for complex patient stratification and multiple different treatment protocols, while maintaining high effectiveness across the entire patient population
Data Source
AI summary
The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment or prevention of migraine, including in subjects whose migraines are not responsive to CGRP inhibition or whose migraines are responsive to triptans. Combination therapies are also described. In other aspects, the present disclosure provides methods for identifying suitable patients, methods for identifying inhibitors of human TRPM3, cell lines and agonists for use in such methods and a method for measuring PACAP release.